Axicabtagene Ciloleucel for CD19+ Plasmablastic Lymphoma

American Journal of Hematology - United States
doi 10.1002/ajh.25682
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma

Clinical Cancer Research
Cancer ResearchOncology
2018English

Safety and Efficacy of Axicabtagene Ciloleucel (Axi-Cel) in Older Patients: Results From the Us Lymphoma Car-T Consortium

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Product Characteristics Associated With in Vivo Expansion of Anti-Cd19 Car T Cells in Patients Treated With Axicabtagene Ciloleucel (Axi-Cel)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Preliminary Results of Earlier Steroid Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Large B Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Plasmablastic Lymphoma Mimicking Acute Pancreatitis

Case Reports in Oncological Medicine
Oncology
2016English

Safety and Efficacy of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphomas

Therapeutic Advances in Hematology
Hematology
2020English

Plasmablastic Lymphoma Versus Diffuse Large B Cell Lymphoma With Plasmablastic Differentiation: Proposal for a Novel Diagnostic Scoring System

Journal of Hematopathology
Forensic MedicinePathologyHematologyHistology
2015English

Plasmablastic Lymphoma in the Anal Canal

Cancer Research and Treatment
Cancer ResearchOncology
2009English

Primary Plasmablastic Thyroid Lymphoma: A Case Report

AACE Clinical Case Reports
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy